Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of ...
Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDE TM) and Targeted Removal of Aberrant Protein (TRAP TM) extracellular protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results